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Introduction
Interfering with the molecular mechanisms regulating the expression
and/or activity of the effectors of proliferation-to-differentiation
transition (PDT) is an attractive approach to inhibit tumor-cell
growth and/or reorientate tumor cells towards a post-mitotic
differentiated state.
SOX transcription factors, which contain a high-mobility group
(HMG) domain, have been clearly evidenced as important regulators
of the PDT during development and adult tissue renewal
(Episkopou, 2005; Kanai et al., 2005; Shimizu et al., 2007; Zorn
and Wells, 2007). In particular, findings from our laboratory
indicate an involvement of SOX9 in the control of proliferation,
differentiation and cell fate of the intestinal epithelium (Bastide et
al., 2007). However, the molecular mechanisms involved in these
biological processes still remain to be elucidated. Up to now,
CEACAM1 is the only SOX9 direct target identified in the intestinal
epithelium whose gene expression is upregulated through the
binding of the SOX9 HMG domain on a sequence similar to the in
vitro characterized consensus sequence [A/T][A/T]CAA[A/T]G
(Kamachi et al., 2000; Zalzali et al., 2008). The expression of genes
encoding, for example, the CDX2 cell-differentiation marker, the
carcinoembryonic antigen (CEA) or the tight-junction protein
claudin 7 is inversely decreased in response to an overexpression
of SOX9, but it was concluded that these repressions might be
indirect, i.e. mediated through the prior transcriptional activation
of as-yet-unidentified repressor genes (Blache et al., 2004; Darido
et al., 2008; Jay et al., 2005). Indeed, SOX9 was always found to
be a transcriptional activator in a number of physiological situations
(De Santa Barbara et al., 1998; Lee et al., 2004; Ng et al., 1997)
and no SOX9 DNA-binding sequence could be identified within
the promoter of these genes.
In vitro and in vivo data indicate that variations in the amount
of the tumor-promoting phorbol-ester receptor protein kinase C
(PKC) also drastically influence the PDT and might have an
important impact on intestinal tumorigenesis. Indeed,
overexpression of both PKCβ2 and PKCε stimulates the
proliferation of colon epithelial cells (Murray et al., 1999; Perletti
et al., 1996) and a high PKCβ2 expression level is considered as
an early promoting event in colon carcinogenesis (Gokmen-Polar
et al., 2001). By contrast, overexpression of PKCα induces cell-
growth arrest and differentiation of intestinal epithelial cells,
whereas opposite effects are observed with antisense
oligonucleotides encoding PKCα (Scaglione-Sewell et al., 1998).
In vivo, cell-growth inhibition and differentiation that occur when
intestinal cells migrate from the proliferative crypt towards the
differentiated and functional villus correlate with an increase in
PKCα expression (Saxon et al., 1994), and knockout of the gene
encoding PKCα is associated with the acquisition of the proliferative
phenotype of intestinal epithelial cells (Oster and Leitges, 2006).
Finally, PKCα is usually decreased in colorectal cancers (CRCs),
suggesting a protective role of this enzyme from intestinal
tumorigenesis (Kahl-Rainer et al., 1994; Suga et al., 1998).
Leontieva and Black identified two distinct pathways that are
able to regulate PKCα contents in intestinal epithelial cells, both
of which occur at the post-translational level but with no obvious
link with the PDT (Leontieva and Black, 2004). The present study
establishes that transcription of the gene encoding PKCα can be
repressed both in vitro and in vivo by SOX9 in proliferating
Variations of protein kinase C (PKC) expression greatly
influence the proliferation-to-differentiation transition (PDT)
of intestinal epithelial cells and might have an important impact
on intestinal tumorigenesis. We demonstrate here that the
expression of PKCα in proliferating intestinal epithelial cells is
repressed both in vitro and in vivo by the SOX9 transcription
factor. This repression does not require DNA binding of the
SOX9 high-mobility group (HMG) domain but is mediated
through a new mechanism of SOX9 action requiring the central
and highly conserved region of SOXE members. Because SOX9
expression is itself upregulated by Wnt-APC signaling in
intestinal epithelial cells, the present study points out this
transcription factor as a molecular link between the Wnt-APC
pathway and PKCα. These results provide a potential
explanation for the decrease of PKCα expression in colorectal
cancers with constitutive activation of the Wnt-APC pathway.
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intestinal epithelial cells and that this repression is mediated
through a DNA-binding-independent transcriptional mechanism.
Results and Discussion
PKCα transcription is repressed by SOX9 in CRC cell lines
A SOX9-dependent transcriptome (http://www.ebi.ac.uk/,
ArrayExpress database, accession number E-MEXP-859) recently
performed in our laboratory suggested that doxycycline-inducible
FLAG-SOX9 expression was able to decrease the level of mRNA
encoding PKCα by more than 50% in the human HT29Cl16E CRC
cell line. As shown in Fig. 1A,B, quantitative reverse transcriptase
(RT)-PCR and western blot experiments demonstrated that a 2.5-
fold increase of FLAG-SOX9 expression in these cells induced a
75% decrease in the amount of mRNA encoding PKCα and a 50%
decrease of PKCα protein, thus confirming a SOX9-mediated
repression of PKCα transcription. Consistent with this result, the
luciferase activity of reporter plasmids containing either the –1571
to +227 or the –227 to +77 minimum promoter of the gene encoding
PKCαwas inhibited by 40-60% in HT29Cl16E and HCT116 human
CRC cell lines that were transiently transfected with SOX9 (Fig.
1C), demonstrating that SOX9-dependent PKCα repression is not
restricted to HT29Cl16E cells and can be mediated through the
minimum –227 to +77 promoter of the gene encoding PKCα. SOX9
overexpression did not significantly influence PKCα-promoter-
dependent luciferase activity in SW480 human CRC cells, but this
might be due to the high endogenous SOX9 in these cells, compared
with HT29Cl16E and HCT116 cells (Fig. 1D). Inversely, the
activities of the –1571 to +227 and –227 to +77 PKCα-
promoter–luciferase constructs were increased from 2 to 4.5-fold
in both HT29Cl16E and HCT116 cells, and up to 8.5 fold in SW480
cells, in response to antisense SOX9 (Blache et al., 2004; Darido
et al., 2008), suggesting that PKCα expression is repressed by
endogenous SOX9 in these cells. Consistent with this, high SOX9
levels correlated inversely with low levels of mRNA encoding
PKCα and of PKCα protein in these CRC cell lines (Fig. 1D-F).
SOX9 is able to repress PKCα expression in vivo
In normal small intestine, SOX9 is highly expressed and
concentrates in cell nuclei of the proliferative crypt compartment,
and gradually disappears along the crypt-villus axis during
differentiation (Fig. 2A). Inversely, the amount of PKCα is very
low within the crypt and progressively increases during
differentiation. Similar patterns were observed in the colon
epithelium and in HT29Cl16E cells, which exhibit the ability to
differentiate into the goblet-cell lineage when maintained as
confluent cultures. This spontaneous differentiation is associated
with a decrease in SOX9 expression (Jay et al., 2005) and correlates
with the disappearance of SOX9 from the nucleus after 23 days in
culture (Fig. 2B), and the concomitant increase in PKCα expression
(Fig. 2C).
There was clear evidence of SOX9-dependent PKCα repression
by the marked increase of PKCα immunostaining from the bottom
to the top of the crypt region in both the small intestine and colon
from mice that were deficient for SOX9 in the intestinal epithelium
(Bastide et al., 2007) (Fig. 2A). The marked PKCα staining of villus
cells is intriguing, but might result from the persistence of PKCα
in SOX9-deficient crypt cells up to the time of their differentiation.
Previous data reported a long half-life for PKCα, from 6 to more
than 24 hours (Borner et al., 1988), whereas renewal of intestinal
epithelium required 3-5 days. Finally, the western blot presented in
Fig. 2D clearly demonstrates the accumulation of PKCα in small-
intestinal and colonic epithelium of SOX9 knockout mice, indicating
the loss of SOX9-dependent negative regulation of PKCα
expression. PKCα is activated along the crypt-to-villus axis of
SOX9-deficient intestinal epithelium (as evidenced by the
accumulated enzyme at the cell-cell contacts and brush-border
plasma membrane), suggesting that this enzyme might exert a
biological function at the bottom of the crypt, where it is normally
poorly expressed.
A new mechanism of SOX9 action
Similar to the other SOX-family members, SOX9 is expected to
regulate transcription in association with other transcription factors
by bending DNA after association of its HMG domain with the
minor groove of the DNA helix at the consensus response sequence
[A/T][A/T]CAA[A/T]G (Kamachi et al., 2000). Although no
obvious SOX-consensus-binding site was identified on the PKCα
(–227 to +77) promoter, SOX9 interaction with the promoter of the
Journal of Cell Science 122 (13)
Fig. 1. SOX9 is able to repress PKCα transcription in CRC cells. (A,B) Effect
of doxycycline-induced FLAG-SOX9 expression on the amounts of (A) PKCα
mRNA and (B) PKCα protein in HT29Cl16E cells. (C) Effect of transiently
transfected FLAG-SOX9 and SOX9 antisense (AS) on pPKCα (–1571 to
+227)- and pPKCα (–227 to +77)-dependent luciferase activities in
HT29Cl16E, HCT116 and SW480 cells. (D-F) Comparative analysis of SOX9
(D), PKCα protein (E) and PKCα mRNA (F) levels in HT29Cl16E, HCT116
and SW480 cells. Student’s t-test: *P<0.05; **P<0.01; ***P<0.001.
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gene encoding PKCα was not necessarily excluded owing to the
degeneracy of the SOX-binding site and recent findings about a
SOX9-dependent transcription of S100A1 and S100B through a
SOX9-binding site distinct from the consensus sequence (Saito et
al., 2007). SOX9-dependent chromatin immunoprecipitation,
however, was unable to co-precipitate the PKCα (–227 to +77)
minimum promoter (data not shown), suggesting no physical
interaction of SOX9 with the PKCα promoter. We therefore
suspected an indirect SOX9-dependent transcriptional repression
as suggested for CDX2, CEA and claudin 7 (Blache et al., 2004;
Darido et al., 2008; Jay et al., 2005). This hypothesis did, however,
still imply DNA-binding of the SOX9 HMG domain. As shown in
Fig. 3A, the campomelic-dysplasia-associated SOX9 W143R
mutant, although unable to bind DNA (Meyer et al., 1997), was
located in the nucleus of HT29Cl16E cells and was still able to
repress both the PKCα –1571 to +227 and –227 to +77 promoters
in a luciferase assay, suggesting that direct DNA binding of the
SOX9 HMG domain is not required for this repression (Fig. 3A,
compare wt and W143R SOX9 constructs). Deleting the C-terminal
transactivation domain (DC304-509W143R) did not have any
significant effect on SOX9-mediated PKCα repression, whereas a
SOX9 C-terminal deletion including the +208 to +303 (208-303)
central region (DC208-509 W143R) completely abolished the
repression of the PKCα –1571 to +227 and –227 to +77 promoters.
Moreover, expression of a construct in which the 208-303 SOX9
region was fused to two SV40 T-antigen nuclear localization
signals (NLSs) in tandem for appropriate targeting to the nucleus
[SOX9(NLSx2)-208-303] upregulated PKCα –1571 to +227 and
–227 to +77 promoter activity and exhibited a dominant-negative
effect on SOX9-dependent PKCα repression. Fig. 3B further
demonstrates that overexpression of SOX9(NLSx2)-208-303
correlates with increased endogenous PKCα expression. Together,
these data indicate that the SOX9 (208-303) region is a crucial
element in SOX9-dependent repression of transcription of the gene
encoding PKCα. This region is highly conserved among the SOXE
members (SOX8, SOX9 and SOX10). In SOX8, it exhibits a
transactivation potential (Schepers et al., 2000) and, in SOX10, it
is involved in the development of glial-cell lineages (Schreiner et
al., 2007). Therefore, another biological function can be attributed
to the SOX9 (208-303) region, i.e. its involvement in a new DNA-
binding-independent transcriptional repression mechanism.
SOX9-dependent PKCα repression involves SP1
The DC304-509W143R SOX9 construct, which lacks the
transactivation domain, is still able to repress PKCα transcription.
Such a construct has previously been useful to show SOX9-
dependent inhibition of RUNX2 transcriptional activity through the
direct interaction of the SOX9 HMG domain and RUNX2 Runt
domain (Zhou et al., 2006). We identified a putative binding site
for the AML1 (also known as RUNX1) transcription factor in
position –215 to –210 of the promoter of the gene encoding PKCα
(Fig. 4A). However, neither an siRNA against AML1 (decreasing
the level of AML1 mRNA by up to 60%) nor a mutation of the
putative AML1-binding site had any effect on the level of mRNA
Fig. 2. SOX9-dependent PKCα transcriptional repression in
vivo. (A,B) SOX9 and PKCα immunostainings in (A) the
small intestine and colon of wild-type (wt) mice (left panels)
compared with SOX9-deficient (SOX9KO) tissues (right
panels) and in (B) proliferating cells (day 2) compared with
‘pseudo-differentiated’ HT29Cl16E cells (day 23). (C) Western
blot analysis of SOX9 and PKCα levels in total extracts from
proliferating and ‘pseudo-differentiated’ HT29Cl16E cells.
(D) Western blot analysis of PKCα levels in the small intestine
and colon epithelium of wild-type mice compared with SOX9-
knockout mice. Scale bars: 120 μm (A); 15 μm (B).
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
2194
encoding PKCα or on PKCα (–227 to +77)-dependent luciferase
activity, indicating that SOX9-dependent PKCα repression is not
mediated through a similar AML1-dependent mechanism (data not
shown). The PKCα promoter, however, does exhibit a functional
SP1-binding site (Clark et al., 2002) (Fig. 4A), and previous GST-
pulldown data from Wissmuller et al. indicate that SP1 is able to
interact with the SOXE members SOX8 and SOX10 (Wissmuller
et al., 2006). In order to determine whether SOX9 might
exert transcriptional repression through SP1, we first
investigated the effect of SOX9 on an artificial promoter
containing only SP1-binding sites (Sowa et al., 1997).
As shown in Fig. 3A, overexpression of wild-type or
mutated SOX9 influenced the activity of the pSP1
promoter in a similar manner as observed for the PKCα
promoter in HT29Cl16E cells. Moreover, a mutation
disrupting the SP1-binding site drastically decreased the
activity of the minimum PKCα promoter and abolished
its sensitivity to the wild-type and SOX9(NLSx2)208-
303 constructs (Fig. 4B). Finally, Fig. 4C demonstrates
that SOX9 co-precipitates with SP1 and is thus able to
physically interact with SP1 in our cellular model.
Wissmuller et al. reported that the SOX8 or SOX10
HMG domain alone was sufficient to co-precipitate SP1
in their GST-pulldown assays, and that the interaction
involved a short conserved sequence located within the
SOXE HMG-domain C-terminus (Wissmuller et al.,
2006). This sequence apparently is able to bind a number
of transcription factors and might be involved in the
SOX9-SP1 interaction. Our data further indicate that, in HT29Cl16E
cells, the SOX9 (208-303) central region is required for SOX9-
mediated PKCα repression, possibly by increasing the affinity
and/or stabilizing the interaction between SOX9 and SP1 within a
transcriptional repressor complex.
In summary, the present study indicates that PKCα is a new SOX9
target gene in intestinal epithelium and reveals a new DNA-binding-
Journal of Cell Science 122 (13)
Fig. 3. PKCα repression does not require binding of the SOX9
HMG domain to DNA but involves the central domain (208-303).
(A) Activity of wild-type (wt), truncated and mutated FLAG-
SOX9 on pPKCα (–1571 to +227)-, pPKCα (–227 to +77)- and
pSP1-dependent luciferase activities in HT29Cl16E cells: all
FLAG-SOX9 constructs retain nuclear localization, as shown by
immunocytochemistry using an anti-FLAG antibody. The C-
terminal deletion including the SOX9 (208-303) central region
disrupts SOX9-induced transcriptional repression and SOX9
(208-303) fused with two SV40 T-antigen NLSs is able to revert
SOX9-dependent transcriptional repression of the activity of all
promoters. (B) Western blot analysis indicating the effect of
SOX9(NLSx2)208-303 expression on endogenous PKCα
expression. Scale bar: 15 μm.
Fig. 4. Involvement of SP1 in the SOX9-dependant transcriptional
repression of the gene encoding PKCα. (A) Schematic representation
of the –227 to +77 PKCα promoter fused to the luciferase-reporter
gene, indicating the previously identified transcription start site, the
binding sites of the transcription factors AP2, ets-1 and SP1 (Clark et
al., 2002), and a potential AML1-binding site in position –215 to
–210. (B) Luciferase assay comparing the properties of the wild-type
PKCα promoter and the –227 to +77 PKCα promoter mutated within
the SP1-binding site [mut (–67/–70)] (Clark et al., 2002). Note the
insensitivity of the mutated promoter in response to wild-type and
SOX9(NLSx2)-208-303. (C) Western blot demonstrating co-
precipitation of SOX9 and SP1 from FLAG-SOX9-induced
HT29Cl16E whole-cell extracts.
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independent mechanism for SOX9. Because SOX9 is upregulated
by the Wnt-APC pathway in intestinal epithelial cells (Blache et
al., 2004), our results provide an explanation for the correlation that
is observed in both normal and malignant intestinal epithelium
between activated Wnt-APC signaling, upregulation of SOX9
(Cardoso et al., 2006) and reduced expression of PKCα (Oster and
Leitges, 2006). PKCα overexpression has been associated with cell-
growth arrest and differentiation (Scaglione-Sewell et al., 1998),
and PKCα knockout has been associated with tumor formation in
the intestine epithelium (Oster and Leitges, 2006). However, in
SOX9-deficient intestine overexpressing PKCα, neither reduced
proliferation nor increased differentiation was observed; instead,
hyperproliferation, no paneth cells and fewer goblet cells were found
(Bastide et al., 2007). This result then raises the issue of the
functional role of SOX9-dependent PKCα repression in colorectal
cancer. Besides PKCα repression, SOX9 also exerts a negative-
feedback loop on the Wnt-APC pathway (Bastide et al., 2007) and,
therefore, it is possible that cell-growth inhibition due to PKCα
overexpression is not sufficient to overcome the increase in
proliferation caused by upregulation of the Wnt-APC pathway in
intestine that is deficient for SOX9. Previous data from our
laboratory indicate that SOX9-dependent inhibition of the Wnt-APC
pathway involves the classic mechanism of SOX9 action, i.e. the
binding of SOX9 to DNA (Bastide et al., 2007). This inhibition
might result from an upregulation of groucho-related inhibitors of
the β-catenin–Tcf complex (Bastide et al., 2007) and of CEACAM1,
a direct SOX9 target (Jin et al., 2008; Leung et al., 2008; Zalzali
et al., 2008). Indeed, the W143R SOX9 mutant, which is unable to
bind DNA, is unable to inhibit the Wnt-APC pathway, although it
is able to repress PKCα expression, as shown in the present study.
Because the DNA-binding-dependent activity of endogenous SOX9
is weak in colon cancer cells (Darido et al., 2008), it may be
postulated that the SOX9-dependent negative-feedback loop on the
Wnt-APC pathway is at least partially lost in CRC cells. By contrast,
PKCα repression, which does not require SOX9 DNA-binding, is
maintained, thus favoring proliferation, inhibiting differentiation and
potentially facilitating tumor progression, particularly in the context
of a constitutively activated Wnt-APC pathway. Elucidating the
causes of the decrease of SOX9 DNA-binding-dependent activity
in CRC cells is now an attractive issue to address, and might provide
a new approach to influence the balance between proliferation and
differentiation of CRC cells.
Materials and Methods
Cell cultures
HT29Cl16E, HCT116, SW480 and the SOX9-inducible HT29Cl16E cells were
cultured and induced as previously described (Jay et al., 2005).
Plasmids
The reporter constructs containing the human pPKCα and the pSP1 promoters were
previously described (Clark et al., 2002). The putative AML1-binding site in position
–215 to –210 was disrupted using the oligonucleotide 5-GTGTTCCCAGC -
ATTGTCAGGCACTCGCTGCCTCCTCC-3 and its complementary sequence, as
was performed for the murine Ada gene (Schaubach et al., 2006). The FLAG-tagged
wild-type and truncated versions of SOX9 exhibiting the W143R mutation are
described elsewhere (Jay et al., 2005; Bastide et al., 2007). The SOX9(NLSx2)208-
303 construct was obtained with a synthetic insert encoding the FLAG and two SV40
T-antigen NLSs (5-ATGGACTACAAGGACGACGATGACAAGGGTAC CGAT -
CCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTA-3)
subcloned in frame with the SOX9 (208-303) region within the pcDNA3 polylinker.
The SOX9 antisense construct has been previously described (Blache et al., 2004).
Luciferase assays
Assays were performed in triplicate, at least three independent times as in Blache et
al. (Blache et al., 2004). Transfection efficiencies were normalized by co-transfecting
the phRG-TK standardization vector (Promega). Results are expressed as the ratio
of luciferase activity relative to the control pGL3 and pcDNA3 empty plasmids.
Western blotting
Equal amounts of total-protein extracts from cultured cells (30 μg) or mice intestinal
epithelium (20 μg) obtained by scraping the inner intestine layer were loaded on a
10% SDS-PAGE and transferred onto PVDF membranes. Primary antibodies were
the mouse anti-PKCα (1:1000; Upstate Biotechnology), mouse anti-FLAG (1:500;
Sigma), rabbit anti-SOX9 (1:1000) (Bastide et al., 2007), mouse anti-actin (1:5000;
Sigma), rabbit anti-SP1 (1:200; Santa Cruz Biotechnology). Secondary antibodies
were the IRdyeTM 800- and IRdyeTM 700DX-conjugated anti-mouse and rabbit
(1:10,000; Tebu-Bio). Results were analyzed using the OdysseyR infrared imaging
system (LI-COR Biosciences).
Immunoprecipitation
Immunoprecipitations were performed with magnetic beads (Ademtech), 1 mg SOX9-
induced HT29Cl16E whole-cell extracts and 2 μg of either the anti-FLAG or the
anti-SP1 antibodies, according to Ademtech recommendations with a mouse anti-
IgG (Santa Cruz Biotechnology) or a rabbit serum as controls.
Real-time RT-PCR
Experiments were performed with the following primer pairs: GAPDH, 5-GAC-
CACAGTCCATGCCATCACT-3 and 5-TCCACCACCCTGTTGCTGTAG-3;
SOX9, 5-GCCAGGTGCTCAAAGGCTA-3 and 5-TCTCGTTCAGAAG -
TCTCCAGAG-3; PKCα, 5-GCTTCCAGTGCCAAGTTTGC-3 and 5-GCACC-
CGGACAAGAAAAAGTAA-3(Bastide et al., 2007). Results are expressed as the
variation of the studied transcript standardized to GAPDH and relative to the control
conditions.
Immunofluorescence
Paraffin-embedded intestine sections were obtained as previously described (Bastide
et al., 2007). HT29Cl16E cells were plated in 24-well plates (50,000/well) on
coverslips. Antibodies were the rabbit anti-SOX9 (1:200), rabbit anti-PKCα (1:400;
Sigma) and the Cy3-conjugated secondary anti-rabbit antibody (1:1000; Santa Cruz
Biotechnology). Preparations were mounted in Mowiol and observed using an
epifluorescent microscope (Zeiss).
siRNA
HT29Cl16E cells (350,000) were seeded in 60-mm dishes and transfected with 100
nM of an siRNA targeting the AML1 messenger sequence 5-CCGCCGCUU -
CACGCCGCCUUC-3 (Wang et al., 2005). After 48 hours, cells were harvested and
mRNA content was analyzed by real-time RT-PCR.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed using the Magna ChIP
G Kit and a ChIPable HT29 chromatin (Upstate) with either the rabbit anti-SOX9
or rabbit serum as a control. Forward 5-GTGTTCCCAGCACCGCAAGG-3 and
reverse 5-GAGAGTCGGGCTGGTGCTG-3 primers were used to amplify the
PKCα –227 to +77 minimum promoter by PCR.
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